This article revolves around the understanding of the general characteristics of COVID-19, as well as a more detailed description and critical assessment of the association between this coronavirus disease and diabetes and its management. For this article, literature review was carried out to search for articles in PubMed and Google Scholar databases till 02 April 2020 with various keywords like “COVID-19”, “clinical features”, “diagnosis”, “treatment”, “diabetes”. It was found that older age, diabetes and other comorbidities are significant predictors of morbidity and mortality. Chronic inflammation, increased coagulation activity, immune response impairment, and potential direct pancreatic damage by SARS-CoV-2 might be among the underlying mechanisms of the association between diabetes and COVID-19. No conclusive evidence exists to support the discontinuation of angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers or thiazolidinediones because of COVID-19 in people with diabetes. Caution should be taken to potential hypoglycemic conditions with the use of chloroquines. Therapeutic diets and strategies given to patient, monitoring of blood glucose levels and careful consideration of drug interactions might reduce adverse outcomes.
